Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

NCT01313273 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Poor enrolment

Conditions

Prostate Cancer

Interventions

DRUG: Lanreotide, non steroidal anti androgens and LHRH-a
DRUG: Non steroidal anti androgens and LHRH-a

Sponsor

Ipsen